

AUG 24 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re: U.S. Patent No. 6,034,239
Issued: Mar. 7, 2000
To: Shigenori OHKAWA et. al.
For: Tricyclic Compounds, Their Production and
Use
From: Serial No. 08/812,168
Filed: Mar. 6, 1997

MAIL STOP: PATENT EXTENSION

Commissioner for Patents
P.O. Box 1450
Arlington, VA 22313-1450

Via Facsimile to Central Fax
1-571-273-8300

Sir:

**PETITION TO EXPUNGE CERTAIN PROPRIETARY INFORMATION FROM
APPLICATION FOR EXTENSION OF PATENT TERM
OF UNITED STATES PATENT NO. 6,034,239 UNDER 37 C.F.R. §1.59**

Your applicant, TAKEDA PHARMACEUTICAL COMPANY LTD. ("TAKEDA"),
petitions to have certain Proprietary Confidential Information Expunged from the Application
File pursuant to 37 C.F.R. §1.59.

This petition is being timely filed before the issuance of a certificate of patent term
extension.

Applicants request that parts of Exhibit C, specifically pages 1, 2, 3, 4 and 6 – 38
(inclusive) be Expunged from the Patent Term Extension Application File.

Each page is clearly identified as containing proprietary confidential information of
Takeda. This information has not been otherwise made public.

BEST AVAILABLE COPY

Public release of this information would be irreparably detrimental to Takeda.


Applicants herewith authorize the Commissioner to charge the appropriate fees under 37 C.F.R. §1.17 for the filing of this petition, and any other required charges, to the Applicant's USPTO deposit account No. 500 799.

Respectfully submitted,

Dated: August 24, 2006

(847)383-3372

(847)383-3391



Mark Chao, Ph.D., Reg. No. 37,293

Elaine M. Ramesh, Ph.D., Reg. No. 43,032

Attorney for Applicants


Customer No. 23,115

Takeda Pharmaceuticals North America, Inc.
Intellectual Property Department
475 Half Day Road
Lincolnshire, IL 60069 USA

CERTIFICATE OF FACSIMILE

TRANSMISSION UNDER 37 CFR 1.8

The undersigned hereby certifies that this paper(s) is(are) being transmitted via facsimile to the Commissioner for Patents, Washington, D.C. 20231 on this date Aug 24, 2006, to the Central Fax Facsimile Number 1-877-273-8500.


Mark Chao, Ph.D., Reg. No. 37,293

AUG 24 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re: U.S. Patent No. 6,034,239
Issued: Mar. 7, 2000
To: Shigenori OHKAWA et. al.
For: Tricyclic Compounds, Their Production
and Use
From: Serial No. 08/812,168
Filed: Mar. 6, 1997

MAIL STOP: PATENT EXTENSION

Commissioner for Patents
P.O. Box 1450
Arlington, VA 22313-1450
Sir:

Via Facsimile to Central Fax
1-571-273-8300

3 Pages

TRANSMITTAL LETTER

1. Enclosed is Request to Expunge certain Proprietary Confidential Information from the Patent Term Extension Application File under 37 CFR §1.59
2. The Commissioner is authorized to charge the appropriate prescribed fees of \$200.00 (37 CFR 1.17(g)), and any other required fees, or to credit any overpayments to Applicant's USPTO Deposit Account No. 500 799 (Takeda Pharmaceutical Company Inc.).

Respectfully submitted,

Dated: August 24, 2006

(847)383-3372
(847)383-3391



Mark Chao, Ph.D., Reg. No. 37,293
Elaine M. Ramesh, Ph.D., Reg. No. 43,032
Attorney for Applicants
Customer No. 23,115

Takeda Pharmaceuticals North America, Inc.
Intellectual Property Department
475 Half Day Road
Lincolnshire, IL 60069 USA